Highlights of This Issue 1

SPECIAL FEATURES

CCR 20th Anniversary Commentary
3 Clinical Cancer Research: The 20th Anniversary

CCR Translations
4 Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake
Anja Mottok and Randy D. Gascoyne
See related article, p. 113

7 New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
Dennis P.M. Hughes, Shivaani Kummar, and Alexander J. Lazar
See related article, p. 60

CCR New Strategies
10 New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
Ramaprasad Srinivasan, Christopher J. Ricketts, Carole Sourbier, and W. Marston Linehan

Molecular Pathways
18 Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels
Brent A. Orr and Charles G. Eberhart

24 Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases
Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff

CANCER THERAPY: CLINICAL

30 Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

39 Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Donald T. Weed, Jennifer L. Vella, Isidirinha M. Reis, Adriana C. De la fuente, Carmen Gomez, Zoukaa Sargi, Ronen Nazarian, Joseph Califano, Ivan Borrello, and Paolo Serafini

49 Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Serena Di Cosimo, Siriam Sadhanyaranayan, Johanna C. Bendell, Andrés Cervantes, Mark N. Stein, Irene Briata, Desamparados Roda, Brian E. Haines, Theresa Zhang, Christopher G. Winter, Sharda Jha, Youyuan Xu, Jason Frazier, Richard A. Klinghoffer, Ann Leighton-Swayze, Yang Song, Scio Ebbinghaus, and José Baselga

60 A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
See related commentary, p. 7

68 A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angela Scardina, Caitlin Joffe, Emily Petit, Amy Hacker-Prietz, Robert J. Kinders, Lihua Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lillian L. Siu, and Nilofer S. Azad

77 First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Debashis Sarker, Joo Ern Ang, Richard Baird, Rebecca Kisteleki, Krunal Shah, Victor Moreno, Paul A. Clarke, Florence J. Raymond, Gallia Levy, Joseph A. Ware, Kathlyn Mazina, Ray Lin, Jenny Wu, Jill Frideckson, Jill M. Spoerke, Mark R. Lackner, Yihing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, and Johann S. de Bono
Table of Contents

193 The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Chi-Pang Wen, Fanmao Zhang, Dong Liang, Christopher Wen, Jian Gu, Heath Skinner, Wong-Ho Chow, Yuanqing Ye, Xia Pu, Michelle A.T. Hildebrandt, Maosheng Huang, Chien-Hua Chen, Chao Agnes Hsiung, Min Kuang Tsai, Chwen Keng Tsao, Scott M. Lippman, and XiFeng Wu

201 Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Te-Sheng Chang, Yu-Chih Wu, Ching-Chi Chi, Wei-Chi Su, Pey-Jium Chang, Kam-Fai Lee, Tao-Hsin Tung, Jui Wang, Jun-Jen Liu, Shui-Yi Tung, Liang-Mou Kuo, Hong-Nerng Ho, Thai-Yen Ling, and Yen-Hua Huang

211 Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, and Wei-Ting Hwang

LETTERS TO THE EDITOR

221 Diffusion-Weighted MRI for Lymphoma Staging—Letter
Hugo J.A. Adams and Thomas C. Kwee

222 Diffusion-Weighted MRI for Lymphoma Staging—Response
Marius E. Mayerhoefer and Markus Raderer

ABOUT THE COVER

The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER+, HER2+, or triple-negative (ER-, PR-, HER2-) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER+ subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue.